SB12, Biosimilar To Eculizumab (Complement 5 Inhibitor) For Generalized Myasthenia Gravis (P4-8.013)
SB12 (eculizumab-aagh), a biosimilar referencing Soliris (ECU-RP, eculizumab reference product) was approved by FDA under the name Epysqli® for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, and acetylcholine receptor antibody positive generalized myasthenia gravis (gMG). We report the results of comparability studies of SB12.
Authors
- Min‐Jung Kang (ORCID: https://orcid.org/0000-0002-1398-2037)
- Jinah Jung
- Hyun‐Soo Kim (ORCID: https://orcid.org/0000-0001-8887-1318)
- Seung-Hoon Baek
Institutions
- Samsung (United States) (US)
- Urology Team (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211586
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00